The novel non-peptide selective endothelin A receptor antagonist LU 135 252 protects against myocardial ischaemic and reperfusion injury in the pig

Acta Physiologica Scandinavica

Volumn 163, Issue 2, 1998, Pages 131-137

  Gonon, A T ^a   Wang, Q D ^a   Shimizu, M ^a   Pernow, J ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Endothelin; ETA receptor antagonist; Ischaemia reperfusion injury; LU 135 252

Indexed keywords

DARUSENTAN; ENDOTHELIN RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CORONARY ARTERY BLOOD FLOW; DRUG EFFICACY; DRUG RECEPTOR BINDING; FEMALE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; MALE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR DENSITY; REPERFUSION INJURY; SWINE; TISSUE DISTRIBUTION;

ANIMALS; CORONARY CIRCULATION; CORONARY VESSELS; ENDOTHELINS; FEMALE; HEMODYNAMIC PROCESSES; MALE; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; PHENYLPROPIONATES; PYRIMIDINES; RECEPTOR, ENDOTHELIN A; RECEPTORS, ENDOTHELIN; SWINE;

EID: 0031812111     PISSN: 00016772     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-201X.1998.00376.x     Document Type: Article

References (29)

1. Arai, H., Hori, S., Aramori, I., Ohkubo, H. & Nakanishi, S. 1990. Cloning and expression of a cDNA encoding an endothelin receptor. Nature 348, 730-732.
2. Burke, S.E. & Nelson, R.E. 1997. Endothelin-receptor antagonist FR 139317 reduces infarct size in a rabbit model when given before, but not after, coronary occlusion. J Cardiovasc Pharmacol 29, 87-92.
3. DeNucci, G., Thomas, R., D'Orleans-Juste, P. et al. 1988. Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc Natl Acad Sci USA 85, 9797-9800.
4. Fishbein, M.C., Meerbaum, S., Rit, J. et al. 1981. Early phase acute myocardial infarct size quantification: Validation of the triphenyltetraxolium chloride tissue enzyme staining technique. Am Heart J 101, 593-600.
5. Galron, R., Bdolah, A., Kloog, Y. & Sokolovsky, M. 1990. Endothelin/sarafotoxin receptor induced phosphoinositide turnover: Effects of pertussis and cholera toxins and phorbol esters. Biochem Biophys Res Commun 171, 949-954.
6. Gómez-Garre, D., Guerra, M., González, E. et al. 1992. Agregation of human polymorphonuclear leukocytes by endothelin: Role of platelet activating factor. Eur J Pharmacol 224, 167-172.
7. Grover, G.J., Dzwonczyk, S. & Parham, C.S. 1993. The endothelin-1 receptor antagonist BQ 123 reduces infarct size in a canine model of coronary occlusion and reperfusion. Cardiovasc Res 27, 1613-1618.
8. Grover, G.J., Sleph, P.G., Fox, M. & Trippodo, N.C. 1992. Role of endothelin-1 and big endothelin-1 in modulating coronary vascular tone, contractile function and severity of ischemia in rat hearts. J Pharmacol Exp Ther 263, 1074-1082.
9. Ihara, M., Noguchi, K., Saeki, T. et al. 1992. Biological profiles of highly potent novel endothelin antagonist selective for the ETA receptor. Life Sci 50, 247-255.
10. Krause, S.M., Lynch, J.J., Jr., Stabilito, I.I. & Woltmann, R.F. 1994. Intravenous administration of the endothelin-1 antagonist BQ 123 does not ameliorate myocardial ischaemic injury following acute coronary occlusion in the dog. Cardiovasc Res 28, 1672-1678.
11. Lerman, A., Edwards, B.S., Hallet, J.W. et al. 1991. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. New Engl J Med 325, 997-1001.
12. Li, X.-S., Wang, Q.-D. & Pernow, -J. 1995. Beneficial effects of the endothelin receptor antagonist bosentan on myocardial and endothelial injury following ischemia/ reperfusion in the rat. Eur Pharmacol 283, 161-168.
13. McMurdo, L., Thiemermann, C. & Vane, J.R. 1994. The effects of the ETA receptor antagonist, FR 139317, on infarct size in a rabbit model of acute myocardial ischaemia and reperfusion. Br J Pharmacol 112, 75-80.
14. Miyauchi, T., Yanagisawa, M., Tomizawa, T. et al. 1989. Increased plasma concentrations of endothelin-1 and big endothelin-1 in acute myocardial infarction. Lancet 2, 53-54.
15. Münter, K., Hergenröder, L., Unger, L. & Kirchengast, M. 1996. Oral treatment with a selective ETA-receptor antagonist inhibits neointima formation induced by endothelial injury. Pharmacol Pharmacolog Lett 6, 90-92.
16. Raschack, M. & Stumpf, C. 1996. Selective endothelin A antagonism by orally given LU 135252 reduces neointima formation in collared carotid arteries of rabbits. Eur J Clin Invest 26, 288.
17. Raschack, M., Unger, L., Riechers, H. & Klinge, D. 1995. Receptor selectivity of endothelin antagonists and prevention of vasoconstriction and endothelin-induced sudden death. J Cardiovasc Pharmacol 26, S397-S399.
18. Richard, V., Kaeffer, N., Hogie, M., Tron, C., Blanc, T. & Thuillez, C. 1994. Role of endogenous endothelin in myocardial and coronary endothelial injury after ischaemia and reperfusion in rats: studies with bosentan, a mixed ETA-ETB antagonist. Br J Pharmacol 113, 869-876.
19. Rubanyi, G.M. & Polokoff, M.A. 1994. Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol Rev 46, 325-415.
20. Saito, T., Furshimi, E. & Abe, T. 1992. Augmented contractile response to endothelin and blunted endothelium-dependent relaxation in post-ischemic reperfused coronary arteries. Jpn Circ J 56, 657-670.
21. Saito, Y., Nakao, K., Mukoyama, M. & Imura, H. 1990. Increased plasma endothelin level in patients with essential hypertension. New Engl J Med 322, 205.
22. Sakurai, T., Yanagisawa, M., Takuwa, Y. et al. 1990. Cloning of a cDNA encoding a nonisopeptide selective subtype of the endothelin receptor. Nature 348, 732-735.
23. Tønnessen, T., Giaid, A., Saleh, D., Naess, P.A., Yanagisawa, M & Christensen, G. 1995. Increased in vivo expression and production of endothelin-1 by porcine cardiomyocytes subjected to ischemia. Circ Res 76, 767-772.
24. Wang, Q.-D., Hemsén, A., Li, X.-S., Lundberg, J.M., Uriuda, Y. & Pernow, J. 1995a. Local overflow and enhanced tissue content of endothelin following myocardial ischaemia and reperfusion in the pig: modulation by l-arginine. Cardiovasc Res 29, 44-49.
25. Wang, Q.-D., Li, X.-S., Lundberg, J.M., & Pernow, J. 1995b. Protective effects of non-peptide endothelin receptor antagonist bosentan on myocardial ischaemic and reperfusion injury in the pig. Cardiovasc Res 29, 805-812.
26. A receptor-mediated coronary vasoconstriction after coronary thrombosis and thrombolysis in pigs. J Cardiovasc Pharmacol 26, 770-776.
27. Watanabe, T., Suzuki, N., Shimamoto, N., Fujino, M. & Imada, A. 1991. Contribution of endogenous endothelin to the extension of myocardial infarct size in rats. Circ Res 69, 370-377.
28. Weitzberg, R., Rudehill, A., Modin, A. & Lundberg, J.M. 1994. Porcine intrinsic pulmonary and systemic vascular tone is endothelin-dependent. Acta Physiol Scand 152, 433-434.
29. Yanagisawa, M., Kurihara, H., Kimura, S. et al. 1988. Endothelin: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 322, 411-415.